Vaccines Today—June 19, 2026

This week’s Vaccine update highlights safety surveillance actions, early-stage clinical progress, therapeutic vaccine advances, strategic partnerships, and upcoming pivotal data across infectious disease and chronic-condition programs.

In Today’s Newsletter

Dive deeper

🦟 Butantan-DV dengue rollout paused in Brazil [1] [Brazil • 15 Jun 2026]

https://www.bmj.com/content/393/bmj-2026-205610
Context: Brazil suspended rollout of Butantan-DV after two healthcare-worker deaths and 42 unexpected adverse events.
Key point: Health officials described the pause as precautionary; causality with the vaccine was not established.
Implication: May influence prescriber choice and payer reviews pending full data.

🌲 ITI-9001 allergy vaccine cleared for Japan Phase 1 [2] [Japan • 15 Jun 2026]

https://www.asiae.co.kr/en/article/2026061508114549418
Context: ITI-9001 (Immunomic Therapeutics, HLB) combines UNITE with self-amplifying RNA to target CryJ2.
Key point: Japan approved a single-center, randomized, placebo-controlled Phase 1 trial in adults aged 18–65.
Implication: Signals pipeline investment and modality expansion.

🧪 Intravacc–SynphaBase conjugate-vaccine partnership [3] [Europe • 15 Jun 2026]

https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/intravacc-and-synphabase-announce-strategic-partnership-to-advance-conjugate-vaccine-development/2365566/amp
Context: SynphaBase brings synthetic oligosaccharides; Intravacc brings conjugation, scale-up, and GMP manufacturing.
Key point: The non-exclusive partnership aims to support third-party and selected internal conjugate-vaccine programs.
Implication: Signals pipeline investment and modality expansion.

🫁 Pneumococcal vaccine protection questioned in high-risk adults [4] [US • 15 Jun 2026]

https://www.drugtopics.com/view/pneumococcal-vaccines-fail-to-clearly-protect-high-risk-adults-under-65
Context: A 2020–2024 multicenter case-control study included more than 1,600 adults aged 18–64 with risk factors.
Key point: PPSV23, PCVs, and sequential strategies showed no statistically significant protection against CAP hospitalization.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧠 ACI-7104 Parkinson’s vaccine trial extended [5] [16 Jun 2026]

https://parkinsonsnewstoday.com/news/new-4m-grant-extending-trial-testing-long-term-safety-parkinsons-vaccine/
Context: ACI-7104 (AC Immune) targets alpha-synuclein oligomers in early Parkinson’s disease.
Key point: A $4M Goradia Foundation grant extends Part 1 of the Phase 2 VacSYn trial by two years.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Hong Kong–Shenzhen therapeutic HIV vaccine reports early signal [6] [Hong Kong–Shenzhen • 16 Jun 2026]

https://www.chinadailyasia.com/hk/article/635076
Context: Investigator-initiated extension studies enrolled 10 volunteer HIV patients; seven completed treatment.
Key point: Two patients achieved significant viral control, and most completers showed some degree of control.
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 Ebola Bundibugyo vaccines could enter Phase 1 [7] [DRC • 16 Jun 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/ebola-bundibugyo-vaccine-candidates-could-enter-phase-1-trials-early-july-2026-06-16/
Context: Oxford University and Moderna candidates target Ebola Bundibugyo amid an eastern DRC outbreak.
Key point: CEPI said lead candidates could enter Phase 1 as early as July, with field trials possible within months.
Implication: Signals pipeline investment and modality expansion.

🛡️ Invivyd completes LIBERTY enrollment for VYD2311 [8] [US • 16 Jun 2026]

https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-completion-enrollment-phase-3-liberty-trial
Context: LIBERTY is a Phase 3 randomized, double-blind study of VYD2311, mRNA vaccine, and co-administration.
Key point: Invivyd completed enrollment of about 210 healthy adults and expects topline data in Q3 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🎗️ CellxLife licenses Mayo Clinic FRα ovarian-cancer vaccine [9] [US • 17 Jun 2026]

https://www.biopharminternational.com/view/cellxlife-licenses-mayo-clinic-fr-alpha-targeting-dendritic-cell-vaccine-ovarian-cancer
Context: The FRα-targeting dendritic cell vaccine is in two Phase 2 trials for ovarian cancer.
Key point: CellxLife licensed the Mayo Clinic vaccine; Phase 1 durability data were company-reported and not independently verified in the article.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Vaccine safety surveillance remains prominent, as Brazil paused Butantan-DV pending investigation.
Therapeutic vaccines are expanding beyond infection prevention into allergy, Parkinson’s, HIV, and oncology.
Conjugate-vaccine infrastructure remains a strategic area for CDMO and synthetic-oligosaccharide partnerships.
Comparative prophylaxis is emerging in COVID-19, with Invivyd testing monoclonal antibody prevention against mRNA vaccination.
Several stories are early-stage or observational, so trial design, endpoints, and full datasets will determine impact.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page.

FAQ

Did Brazil prove Butantan-DV caused the two deaths?

No. Brazil paused the rollout as a precaution while officials investigate deaths, adverse events, risk factors, quality issues, and possible immunization errors. Causality was not established. [1]

What is ITI-9001 designed to treat?

ITI-9001 (Immunomic Therapeutics, HLB) is a therapeutic vaccine candidate for Japanese cedar pollen allergy. It targets CryJ2 using UNITE and self-amplifying RNA technology. [2]

What did the pneumococcal vaccine study find?

The study reported no statistically significant protection against CAP-related hospitalization in high-risk adults aged 18–64. The article notes possible confounding, especially in immunocompromised groups. [4]

What is ACI-7104 in Parkinson’s disease?

ACI-7104 (AC Immune) is an experimental vaccine targeting alpha-synuclein clumping. The new grant extends long-term safety and effectiveness follow-up in the VacSYn trial. [5]

What is Invivyd testing in LIBERTY?

LIBERTY compares VYD2311, an investigational COVID-19 monoclonal antibody, with an mRNA COVID-19 vaccine and also evaluates co-administration. Topline data are expected in Q3 2026. [8]

What did CellxLife license from Mayo Clinic?

CellxLife licensed an FRα-targeting dendritic cell vaccine for ovarian cancer. Two Phase 2 trials are ongoing, and no interim Phase 2 efficacy or safety data were disclosed. [9]

Entities / Keywords

Butantan-DV, Butantan Institute, Brazil dengue vaccine, Anvisa
ITI-9001, Immunomic Therapeutics, HLB, UNITE, saRNA, CryJ2, Japanese cedar pollen allergy
Intravacc, SynphaBase, conjugate vaccines, synthetic oligosaccharides, GMP manufacturing
PPSV23, PCVs, pneumococcal vaccines, CAP hospitalization, high-risk adults under 65
ACI-7104, AC Immune, VacSYn, Parkinson’s disease, alpha-synuclein
Therapeutic HIV vaccine, HKUMed, Shenzhen Third People’s Hospital, nucleic acid vaccine
Ebola Bundibugyo, Oxford University, Moderna, CEPI, DRC
VYD2311, Invivyd, LIBERTY, DECLARATION, COVID-19 monoclonal antibody
CellxLife, Mayo Clinic, FRα, dendritic cell vaccine, ovarian cancer